The average one-year price target for Prothena (NasdaqGS:PRTA) has been revised to $20.74 / share. This is an increase of 10.91% from the prior estimate of $18.70 dated November 14, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $8.08 to a high of $37.80 / share. The average price target represents an increase of 87.35% from the latest reported closing price of $11.07 / share.
What is the Fund Sentiment?
There are 387 funds or institutions reporting positions in Prothena. This is an decrease of 40 owner(s) or 9.37% in the last quarter. Average portfolio weight of all funds dedicated to PRTA is 0.06%, an increase of 6.16%. Total shares owned by institutions increased in the last three months by 0.99% to 46,048K shares. 
The put/call ratio of PRTA is 1.12, indicating a bearish outlook.
What are Other Shareholders Doing?
VGHCX - Vanguard Health Care Fund Investor Shares holds 4,184K shares representing 7.77% ownership of the company. In its prior filing, the firm reported owning 4,220K shares , representing a decrease of 0.85%. The firm decreased its portfolio allocation in PRTA by 29.70% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 2,324K shares representing 4.32% ownership of the company. In its prior filing, the firm reported owning 2,318K shares , representing an increase of 0.27%. The firm decreased its portfolio allocation in PRTA by 70.57% over the last quarter.
Armistice Capital holds 1,824K shares representing 3.39% ownership of the company. In its prior filing, the firm reported owning 2,236K shares , representing a decrease of 22.59%. The firm decreased its portfolio allocation in PRTA by 6.89% over the last quarter.
Rubric Capital Management holds 1,540K shares representing 2.86% ownership of the company.
ADAR1 Capital Management holds 1,469K shares representing 2.73% ownership of the company. In its prior filing, the firm reported owning 3,375K shares , representing a decrease of 129.73%. The firm decreased its portfolio allocation in PRTA by 57.13% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
